ReviewInternational journal of oncology2025
Epithelial‑mesenchymal plasticity and cisplatin resistance in germ cell tumors: Mechanisms and emerging therapeutic strategies (Review).
Review in International journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Talin1 is downregulated in testicular germ cell tumors according to combined bioinformatics and experimental approaches.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germ cell tumors (GCTs) are rare, heterogeneous neoplasms derived from primordial germ cells. Although they typically develop in the gonads, they may also arise in extragonadal locations along the midline of the body. Approximately 90% of patients respond well to cisplatin‑based chemotherapy; however, ~30% exhibit treatment resistance. Epithelial‑mesenchymal plasticity (EMP), a recognized hallmark of cancer, has been implicated in promoting metastasis and chemoresistance. Nonetheless, studies investigating the specific role of EMP in GCT treatment resistance remain limited. The present review compiles key studies on GCTs, EMP markers and cisplatin resistance using both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.